<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &#x00026; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24684803</article-id><article-id pub-id-type="pmc">4025538</article-id><article-id pub-id-type="publisher-id">1758-5996-6-48</article-id><article-id pub-id-type="doi">10.1186/1758-5996-6-48</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Ihana</surname><given-names>Noriko</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>nori_3373@yahoo.co.jp</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Tsujimoto</surname><given-names>Tetsuro</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>yebisu0406@yahoo.co.jp</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Yamamoto-Honda</surname><given-names>Ritsuko</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rithonda@hosp.ncgm.go.jp</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Kishimoto</surname><given-names>Miyako</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mkishimo@hosp.ncgm.go.jp</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Kajio</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hkajio@hosp.ncgm.go.jp</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Noto</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>nhiroshi@hosp.ncgm.go.jp</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Kakei</surname><given-names>Masafumi</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>mkakei@jichi.ac.jp</email></contrib><contrib contrib-type="author" corresp="yes" id="A8"><name><surname>Noda</surname><given-names>Mitsuhiko</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>mnoda@hosp.ncgm.go.jp</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Center Hospital, Tokyo, Japan</aff><aff id="I2"><label>2</label>Division of General Medicine, Jichi Medical University Graduate School of Medicine, Tochigi, Japan</aff><aff id="I3"><label>3</label>First Department of Comprehensive Medicine, Saitama Medical Center, Jichi Medical University School of Medicine, Saitama, Japan</aff><aff id="I4"><label>4</label>Department of Diabetes Research, Diabetes Research Center, National, Center for Global Health and Medicine, Tokyo, Japan</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>31</day><month>3</month><year>2014</year></pub-date><volume>6</volume><fpage>48</fpage><lpage>48</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Ihana et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Ihana et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.dmsjournal.com/content/6/1/48"/><abstract><sec><title>Background</title><p>Combination therapy consisting of basal insulin and oral hypoglycemic agents (OHAs) is effective for the treatment of type 2 diabetes (T2DM) that cannot be adequately controlled using OHAs alone. Though basal insulin with metformin or sulfonylurea is an effective therapy, it cannot reduce postprandial glycemia without the risk of hypoglycemia. We examined a two-step regimen consisting of the addition of postprandial hypoglycemic agents (an alpha-glucosidase inhibitor and a glinide) in patients whose T2DM was poorly controlled using basal insulin therapy.</p></sec><sec><title>Methods</title><p>Inpatients between the ages of 30&#x02013;79&#x000a0;years who had T2DM and an HbA1c level of more than 7.0% were recruited. The patients were treated with once-daily insulin glargine with or without metformin, depending on the patient&#x02019;s age and renal function. Insulin glargine was titrated to achieve a target fasting glucose level of 70&#x02013;130&#x000a0;mg/dL as a first step (STEP0). If the 2-hour postprandial glucose (PBG) level was higher than the target of 180&#x000a0;mg/dL, miglitol treatment (150&#x000a0;mg/day) was initiated, with dose adjustments (75&#x02013;225&#x000a0;mg) allowed depending on abdominal symptoms and the PBG (STEP1). If the PBG of the patients remained higher than the target after 3&#x000a0;days of treatment, mitiglinide (30&#x000a0;mg/day, titrated up to 60&#x000a0;mg) was added (STEP2). We then evaluated the proportion of patients who achieved the target PBG before and after the two-step regimen. Continuous Glucose Monitoring (CGM) was performed throughout the two-step protocol in most of the patients.</p></sec><sec><title>Results</title><p>Of the 16 patients who were recruited (median age, 67.0 [58.0-71.0] years; body mass index, 25.0 [22.0-27.9] kg/m<sup>2</sup>; HbA1c level at admission, 9.1% [8.35-10.4%]), 1 patient (6.25%) achieved the target PBG at STEP 0 and 14 patients (87.5%) had achieved the target PBG at the end of the treatment protocol (<italic>P</italic>&#x02009;=&#x02009;0.002). CGM showed a significant decrease in the glucose level at each step of the protocol. The standard deviations in the CGM glucose levels for 24&#x000a0;hours, MAGE, and M-value also improved.</p></sec><sec><title>Conclusions</title><p>The two-step addition of postprandial hypoglycemic agents to basal insulin therapy is potentially effective and safe for decreasing both the fasting and postprandial glucose levels.</p></sec></abstract><kwd-group><kwd>Miglitol</kwd><kwd>Mitiglinide</kwd><kwd>Insulin glargine</kwd><kwd>Postprandial hyperglycemia</kwd><kwd>Glucose fluctuation</kwd><kwd>Continuous glucose monitoring (CGM)</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Type 2 diabetes is characterized by both decreased insulin secretion and sensitivity [<xref ref-type="bibr" rid="B1">1</xref>]. The impairment of insulin secretion derived from &#x003b2; cell dysfunction is a progressive process that occurs before diagnosis and throughout the course of type 2 diabetes [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Therefore, many patients who are initially treated with oral hypoglycemic agents (OHAs) eventually require a treatment strategy that includes insulin to counteract persistent hyperglycemia.</p><p>One treatment strategy that includes insulin is the combination of basal insulin with oral hypoglycemic agents. Historically, a regimen combining basal insulin with sulfonylurea and metformin has been frequently used. Using this regimen, the insulin dose can be easily titrated to minimize the number of hypoglycemic episodes and weight gain, compared with multiple insulin injections or mixed insulin therapy [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. However, a drawback of this regimen is that it provides poor support against sustained post-breakfast hyperglycemia (a situation that is often observed in patients with poor glycemic control [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]) and postprandial hyperglycemia, resulting in glucose fluctuations that can increase the risks of both cardiovascular disease [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>] and microvascular disease [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Attempts to lower the postprandial glucose level by increasing the dose of basal insulin can lead to an increased risk of severe hypoglycemia during the night and early morning, which might also be associated with an increased risk of cardiovascular disease [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>].</p><p>Accordingly, we have proposed a regimen consisting of a two-step administration of postprandial hypoglycemic agents, namely an alpha-glucosidase inhibitor and a glinide, to basal insulin therapy to target postprandial hyperglycemia. We then conducted a pilot study to examine the safety and efficacy of this regimen.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>We enrolled patients with type 2 diabetes who were hospitalized at the National Center for Global Health and Medicine Center Hospital between November 2011 and August 2013. Candidate subjects were between the ages of 30&#x02013;79&#x000a0;years and had insufficient glucose control (HbA1c &#x02267; 7.0%). Patients with severe renal dysfunction (estimated glomerular filtration rate &#x0003c;30&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup> or continuous hemodialysis), severe liver dysfunction, type 1 diabetes, glutamic acid decarboxylase antibody positivity, malignancy, or other causes of hyperglycemia were excluded from the present study.</p><p>All the patients provided written informed consent a few days after hospitalization and prior to enrollment in the trial. The study protocol was approved by the ethics committee of the National Center of Global Health and Medicine Center Hospital and was implemented in accordance with the provisions of the Declaration of Helsinki.</p></sec><sec><title>Study design</title><sec><title><bold>
<italic>STEP 0</italic>
</bold></title><p>First, patients were treated with diet therapy (25&#x02013;30&#x000a0;kcal/ideal body weight/day: carbohydrates, 60%-67.5%; fat, 21%-24.2%; protein, 11.2%-18.4%) and insulin glargine with metformin. The metformin dosage was set as high as possible after considering the patient&#x02019;s age, renal function, and other adverse effects. Metformin was not administered to subjects who were older than 75&#x000a0;years of age or who had a serum creatinine level higher than 1.3&#x000a0;mg/dL (for men) or 1.2&#x000a0;mg/dL (for women).</p><p>For the basal insulin therapy, insulin glargine was used. The dose was titrated at the physician&#x02019;s discretion to achieve a target fasting blood glucose (FBG) level between 70&#x02013;130&#x000a0;mg/dL. An evaluation of the daily glucose profiles indicated that at least 5&#x000a0;days after admission were required to regulate the FBG at the target level. If the postprandial 2-hour blood glucose (PBG) level corresponded to the target value (lower than 180&#x000a0;mg/dL), the study protocol ended (STEP 0 responder). Patients who did not achieve the target PBG value were additionally treated with postprandial hypoglycemic agents (refer to STEP 1 and STEP 2 below). The target PBG was defined according to the American Diabetes Association&#x02019;s recommendation [<xref ref-type="bibr" rid="B16">16</xref>].</p></sec><sec><title><bold>
<italic>STEP 1</italic>
</bold></title><p>On day 1, miglitol (150&#x000a0;mg/day, 50&#x000a0;mg administered immediately before every meal) was administered and the PBG was evaluated. If the target PBG was not achieved on day 1, the dose of miglitol was increased to 225&#x000a0;mg/day (75&#x000a0;mg administered immediately before every meal) on day 2. If the patient experienced gastrointestinal symptoms, the dose of miglitol was decreased to a tolerable dose on day 3. The PBG was evaluated on day 2 or day 3. If the PBG was under 180&#x000a0;mg/dL, the study protocol was regarded as having been successful at STEP 1.</p></sec><sec><title><bold>
<italic>STEP 2</italic>
</bold></title><p>For patients who failed to achieve the target PBG with miglitol, mitiglinide (30&#x000a0;mg/day, 10&#x000a0;mg administered immediately before every meal) was added to the treatment regimen on day 4 (or day 5). If the target PBG was not reached, the dosage of mitiglinide was increased to 60&#x000a0;mg/day (20&#x000a0;mg administered immediately before every meal) on day 5 (or day 6) and the PBG was evaluated.</p></sec></sec><sec><title>Biochemical and clinical measurements</title><p>We calculated the BMI using the body height and weight of each patient. The 24-h urine C peptide and serum C peptide levels were measured before and 6&#x000a0;minutes after the intravenous injection of 1&#x000a0;mg of glucagon (glucagon stimulation test).</p><p>The self-monitoring blood glucose (SMBG) levels were checked before and 2&#x000a0;hours after each meal and before sleep (7-point SMBG) using a Nipro StatStrip XP (Nova Biomedical K.K.). The M-value was calculated using the following equation:</p><p><disp-formula><mml:math id="M1" name="1758-5996-6-48-i1" overflow="scroll"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi mathvariant="normal">M</mml:mi><mml:mo>&#x02012;</mml:mo><mml:mtext mathvariant="normal">value</mml:mtext><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">GR</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">W</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="1.5em"/><mml:msub><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">GR</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mrow><mml:mo mathsize="big">&#x02211;</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munderover></mml:mrow><mml:mrow><mml:mfenced open="|" close="|"><mml:mrow><mml:msup><mml:mrow/><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msup><mml:mtext>log</mml:mtext><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">BS</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>100</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">W</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">G</mml:mi></mml:mrow><mml:mrow><mml:mtext mathvariant="normal">max</mml:mtext></mml:mrow></mml:msub><mml:mo>&#x02012;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">G</mml:mi></mml:mrow><mml:mrow><mml:mtext mathvariant="normal">min</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>20</mml:mn></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>(M<sub>GR</sub>&#x02009;=&#x02009;M-value for glucose reading, M<sub>W</sub>&#x02009;=&#x02009;correction factor, BS<sub>ti</sub>&#x02009;=&#x02009;glucose reading at time t<sub>i</sub>, G<sub>max</sub>&#x02009;=&#x02009;maximum glucose reading, G<sub>min</sub>&#x02009;=&#x02009;minimum glucose reading) [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>].</p><p>The patients were observed using continuous glucose monitoring (CGMS&#x000ae; System Gold&#x02122;; Medtronic Inc.); the CGMS device was calibrated four times a day. The results were then used to calculate the 24-h average, the standard deviation (SD) of the 24-h values, the 24-h area under the curve (AUC), every 4-h postprandial value, and from midnight to early morning (from 0:00&#x000a0;AM to 8:00&#x000a0;AM), and the mean amplitude of glycemic excursion (MAGE [<xref ref-type="bibr" rid="B19">19</xref>]) using the glucose values observed every 5&#x000a0;minutes. We failed to obtain CGM records in 2 of the 16 patients because of technical difficulties.</p></sec><sec><title>Primary and secondary outcomes</title><p>The primary endpoint was the change in the proportion of patients who reached the target PBG before and after the addition of the postprandial hypoglycemic agents (STEP 0 vs. end of protocol). We also calculated the M-value, MAGE, and the averages and SDs of the CGM data obtained on the days on which each of the steps were evaluated. We also compared the patient backgrounds of those in whom the treatment was or was not a success.</p></sec><sec><title>Statistical analysis</title><p>Exact McNemar test was used to compare the proportion of patients who achieved the target PBG at STEP 0 and at the end of the protocol. Continuous variables were compared using the Wilcoxon rank sum test. A two-sided <italic>P</italic> value &#x0003c;0.05 was regarded as significant. The results were described using the median and interquartile ranges. The statistical analysis was performed using Stata IC 11.</p></sec></sec><sec sec-type="results"><title>Results</title><p>We enrolled 18 patients with type 2 diabetes who had been hospitalized in our institution. Two patients were excluded: one patient was diagnosed as having preclinical Cushing syndrome, and the other was excluded because of the presence of an insulin autoimmune antibody. One patient reached the target PBG at STEP 0 and did not proceed to the next step in the protocol (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>) (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). Of the 15 patients who were treated with miglitol, 8 patients reached the target PBG at the STEP 1 evaluation. Mitiglinide was then added to the treatments of the 7 patients who failed to reach the target PBG using the STEP 1 treatment; 5 of these patients achieved the target PBG at the STEP 2 evaluation. Finally, 1 of the 16 patients achieved the target PBG at STEP 0 and 14 patients achieved the target PBG at the end of the study protocol (6.25% vs. 87.5%, <italic>P</italic>&#x02009;=&#x02009;0.0002). The 7-point SMBG and CGM were also improved (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>). The characteristics of the patients who reached the target PBG at STEP 1 and the patients who proceeded to STEP 2 are presented in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Enrollment and outcomes.</p></caption><graphic xlink:href="1758-5996-6-48-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p><bold>Characteristic of patients </bold>(<bold>N</bold>&#x02009;=&#x02009;<bold>16</bold>)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>
<italic>Demographics</italic>
</bold></th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Age (years)<sup>a</sup><hr/></td><td align="left" valign="bottom">67.0 (58.0-71.0)<hr/></td></tr><tr><td align="left" valign="bottom">Sex (men/women)<hr/></td><td align="left" valign="bottom">11/5<hr/></td></tr><tr><td align="left" valign="bottom">BMI (kg/m<sup>2</sup>)<sup>a</sup><hr/></td><td align="left" valign="bottom">25.0 (22.0-27.9)<hr/></td></tr><tr><td align="left" valign="bottom">Duration of diabetes (years)<sup>a</sup><hr/></td><td align="left" valign="bottom">14.0 (8.5-24.75)<hr/></td></tr><tr><td align="left" valign="bottom">HbA1c (%)<sup>a</sup><hr/></td><td align="left" valign="bottom">9.1 (8.3-10.4)<hr/></td></tr><tr><td align="left" valign="bottom">Glycated albumin (%)<sup>a</sup><hr/></td><td align="left" valign="bottom">22.9 (19.8-26.8)<hr/></td></tr><tr><td align="left" valign="bottom">eGFR (mL/min/1.73&#x000a0;m<sup>2</sup>)<sup>a</sup><hr/></td><td align="left" valign="bottom">70.0 (62.6-82.4)<hr/></td></tr><tr><td align="left" valign="bottom">Previous medication of diabetes<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"> Insulin<sup>b</sup><hr/></td><td align="left" valign="bottom">7<hr/></td></tr><tr><td align="left" valign="bottom"> Oral hypoglycemic agents<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"> Sulfonylurea<sup>b</sup><hr/></td><td align="left" valign="bottom">5<hr/></td></tr><tr><td align="left" valign="bottom"> Metformin<sup>b</sup><hr/></td><td align="left" valign="bottom">9<hr/></td></tr><tr><td align="left" valign="bottom"> Alpha-glucosidase inhibitor<sup>b</sup><hr/></td><td align="left" valign="bottom">4<hr/></td></tr><tr><td align="left" valign="bottom"> Glinide<sup>b</sup><hr/></td><td align="left" valign="bottom">2<hr/></td></tr><tr><td align="left" valign="bottom"> DPP-4 inhibitor<sup>b</sup><hr/></td><td align="left" valign="bottom">0<hr/></td></tr><tr><td align="left">Administration of metformin at STEP 0<sup>b</sup></td><td align="left">10</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>: Median (interquartile range), <sup>b</sup>: Numbers.</p></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Median 7</bold>-<bold>point SMBG and CGM of all the patients at STEP0 and at the end of the treatment regimen. A</bold>. Median 7-point SMBG of all the patients at STEP 0 and at the end of the treatment regimen. Black line: all the patients at STEP 0, Gray line: all the patients at the end of the treatment regimen. BB: before breakfast, AB: after breakfast, BL: before lunch, AL: after lunch, BD: before dinner, AD: after dinner, BS: before sleep. *value of SMBG of all the patients at STEP 0 vs. those at the end of the treatment regimen <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>B</bold>. Median CGM of all the patients at STEP 0 and at the end of the treatment regimen. Black line: all the patients at STEP 0, Gray line: all the patients at the end of the treatment regimen.</p></caption><graphic xlink:href="1758-5996-6-48-2"/></fig><p>At STEP 0, the 7-point glucose monitoring values exhibited sustained levels of post-breakfast hyperglycemia. With the administration of miglitol, the 7-point glucose monitoring values from after breakfast until after dinner were suppressed, but the values before sleep and before breakfast did not decrease significantly (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>A). When the glycemic profiles were examined more precisely using CGM, the 24-h AUC and each of the 4-h postprandial AUC values were significantly decreased. The AUC from 0:00&#x000a0;AM to 8:00&#x000a0;AM (from evening until before breakfast) remained unchanged at the STEP1 evaluation after the addition of miglitol, compared with the values at STEP0 (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>B).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Median 7</bold>-<bold>point SMBG and CGM at STEP 1 and STEP 2. A</bold>. Median 7-point SMBG of patients who proceeded to STEP 1 (before and after administration of Miglitol). Blue line: The patients who proceeded to STEP 1 before administration of Miglitol, Red line: The patients who proceeded to STEP 1 after administration of Miglitol. BB: before breakfast, AB: after breakfast, BL: before lunch, AL: after lunch, BD: before dinner, before AD: after dinner, BS: before sleep. *value of SMBG of patients who proceeded to STEP 1 before vs. after administration of Miglitol <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>B</bold>. Median CGM of patients who proceeded to STEP1 (before and after administration of Miglitol). Blue line: The patients who proceeded to STEP1 before administration of Miglitol, Red line: The patients who proceeded to STEP1 after administration of Miglitol. <bold>C</bold>. Median 7-point SMBG of patients who proceeded to STEP 2 (before and after administration of Mitiglinide). Red line: The patients who proceeded to STEP 2 before administration of Mitiglinide, Green line: The patients who proceeded to STEP 2 after administration of Mitiglinide. BB: before breakfast, AB: after breakfast, BL: before lunch, AL: after lunch, BD: before dinner, AD: after dinner, BS: before sleep. *value of SMBG of patients who proceeded to STEP 2 before vs. after administration of Mitiglinide <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>D</bold>. Median CGM of patients who proceeded to STEP 2 (before and after administration of Mitiglinide). Red line: The patients who proceeded to STEP 2 before administration of Mitiglinide. Green line: The patients who proceeded to STEP 2 after administration of Mitiglinide.</p></caption><graphic xlink:href="1758-5996-6-48-3"/></fig><p>Similarly, compared with STEP 1, the 7-point glucose monitoring values from after lunch through until after dinner were significantly decreased at the STEP 2 evaluation (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>C), the same day of CGM profile was described (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>D). The 24-h AUC, the 4-h after-lunch AUC, and the 4-h after dinner AUC recorded using CGM were significantly decreased at the STEP 2 evaluation. The details of the CGM data for each step are described in an Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>: Table S2.</p><p>The markers of glucose fluctuations, namely the SDs of the glucose levels for 24-h and MAGE, improved and the M-values were also decreased at the end of protocol (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Results of area under the curve of CGM and glucose fluctuations at STEP 0 and at the end of this protocol</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="left"><bold>
<italic>At the evaluation of STEP 0</italic>
</bold></th><th align="left"><bold>
<italic>At the end of this protocol</italic>
</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Results of continuous glucose monitoring</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Number of patients<hr/></td><td align="left" valign="bottom">14<hr/></td><td align="left" valign="bottom">14<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">AUC for 24-h glycemic fluctuation (mg&#x030fb;h/dL)<hr/></td><td align="left" valign="bottom">4112.1<hr/></td><td align="left" valign="bottom">2986.3*<hr/></td></tr><tr><td align="left" valign="bottom">(3568.8-4338.5)<hr/></td><td align="left" valign="bottom">(2843.3-3504.0)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">AUC for 4-h after breakfast glycemic fluctuation (mg&#x030fb;h/dL)<hr/></td><td align="left" valign="bottom">732.3<hr/></td><td align="left" valign="bottom">521.5<sup>*</sup><hr/></td></tr><tr><td align="left" valign="bottom">(607.4-845.4)<hr/></td><td align="left" valign="bottom">(498.9-626.9)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">AUC for 4-h after lunch glycemic fluctuation (mg&#x030fb;h/dL)<hr/></td><td align="left" valign="bottom">785.9<hr/></td><td align="left" valign="bottom">516.2<sup>*</sup><hr/></td></tr><tr><td align="left" valign="bottom">(573.5-952.0)<hr/></td><td align="left" valign="bottom">(466.5-550.6)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">AUC for 4-h after dinner glycemic fluctuation (mg&#x030fb;h/dL)<hr/></td><td align="left" valign="bottom">785.3<hr/></td><td align="left" valign="bottom">559.2<sup>*</sup><hr/></td></tr><tr><td align="left" valign="bottom">(719.4-877.8)<hr/></td><td align="left" valign="bottom">(485.3-651.4)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">AUC for 8-h from midnight to early morning glycemic fluctuation (00:00&#x02013;08:00) (mg&#x030fb;h/dL)<hr/></td><td align="left" valign="bottom">1033.0<hr/></td><td align="left" valign="bottom">949.8<hr/></td></tr><tr><td align="left" valign="bottom">(911.4-1187.5)<hr/></td><td align="left" valign="bottom">(869.6-1074.3)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">24-h mean glucose levels (mg/dL)<hr/></td><td align="left" valign="bottom">169.7<hr/></td><td align="left" valign="bottom">124.7<sup>*</sup><hr/></td></tr><tr><td align="left" valign="bottom">(142.6-181.1)<hr/></td><td align="left" valign="bottom">(118.8-146.4)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">SDs of 288 glucose levels for 24-h (mg/dL)<hr/></td><td align="left" valign="bottom">38.6<hr/></td><td align="left" valign="bottom">23.5*<hr/></td></tr><tr><td align="left" valign="bottom">(29.9-58.5)<hr/></td><td align="left" valign="bottom">(13.9-28.4)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">Proportion of time (%) in hyperglycemia (&#x0003e;180&#x000a0;mg/dL)<hr/></td><td align="left" valign="bottom">40.7<hr/></td><td align="left" valign="bottom">7.9<sup>*</sup><hr/></td></tr><tr><td align="left" valign="bottom">(17.4-53.7)<hr/></td><td align="left" valign="bottom">(0&#x02013;17.2)<hr/></td></tr><tr><td align="left" valign="bottom">Proportion of time (%) in hypoglycemia (&#x0003c;70&#x000a0;mg/dL)<hr/></td><td align="left" valign="bottom">0<hr/></td><td align="left" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">MAGE<hr/></td><td align="left" valign="bottom">91.1 (79.1-119.6)<hr/></td><td align="left" valign="bottom">61.3<sup>*</sup> (50.2-72.4)<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Results of 7</bold>-<bold>point SMBG</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Number of patients<hr/></td><td align="left" valign="bottom">16<hr/></td><td align="left" valign="bottom">16<hr/></td></tr><tr><td align="left">M-value</td><td align="left">28.8 (21.4-52.5)</td><td align="left">8.7 <sup>*</sup>(5.0-15.7)</td></tr></tbody></table><table-wrap-foot><p>Median (interquartile range)</p><p>*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p><p>CGM data were analyzed in a total of 14 patients because of missing CGM data in 2 of the 16 patients.</p></table-wrap-foot></table-wrap><p>Two patients were unable to achieve the target PBG. One patient was a 78-year-old man; although he exhibited a comparably sufficient endogenous insulin level, he was obese and could not use metformin because of his age. The other patient was a 61-year-old woman; she had a long duration of diabetes, and her endogenous insulin level was almost depleted. Both of these patients had highly fluctuating glucose levels, as shown by the M-value and the SDs of the 24-h data and MAGE obtained using CGM (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Characteristics of patients who did or did not reach the target PBG</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left">&#x000a0;</th><th rowspan="2" align="left" valign="top"><bold>
<italic>Patients who reached the target PBG using this protocol </italic>
</bold><bold>(</bold><bold>
<italic>N</italic>
</bold>&#x02009;<bold>=</bold>&#x02009;<bold>
<italic>14</italic>
</bold><bold>)</bold></th><th colspan="2" align="left" valign="bottom"><bold>
<italic>Patients who failed to reach the target PBG</italic>
</bold><hr/></th></tr><tr><th align="left"><bold>
<italic>&#x02460;</italic>
</bold></th><th align="left">&#x02461;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Age (years)<hr/></td><td align="left" valign="bottom">67.0 (55.5-70.5)<hr/></td><td align="left" valign="bottom">78<hr/></td><td align="left" valign="bottom">61<hr/></td></tr><tr><td align="left" valign="bottom">Sex (men/women)<hr/></td><td align="left" valign="bottom">10/4<hr/></td><td align="left" valign="bottom">man<hr/></td><td align="left" valign="bottom">woman<hr/></td></tr><tr><td align="left" valign="bottom">BMI (kg/m<sup>2</sup>)<hr/></td><td align="left" valign="bottom">25.0 (21.8-27.8)<hr/></td><td align="left" valign="bottom">28.0<hr/></td><td align="left" valign="bottom">22.1<hr/></td></tr><tr><td align="left" valign="bottom">Duration of diabetes (years)<hr/></td><td align="left" valign="bottom">13.0 (7.0-21.5)<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">40<hr/></td></tr><tr><td align="left" valign="bottom">HbA1c (%)<hr/></td><td align="left" valign="bottom">9.2 (8.7-11.2)<hr/></td><td align="left" valign="bottom">8.3<hr/></td><td align="left" valign="bottom">8.2<hr/></td></tr><tr><td align="left" valign="bottom">Glycated albumin (%)<hr/></td><td align="left" valign="bottom">23.0 (20.2-29.4)<hr/></td><td align="left" valign="bottom">21.1<hr/></td><td align="left" valign="bottom">19.8<hr/></td></tr><tr><td align="left" valign="bottom">eGFR (mL/min/1.73&#x000a0;m<sup>2</sup>)<hr/></td><td align="left" valign="bottom">70.5 (58&#x02013;84.2)<hr/></td><td align="left" valign="bottom">70.0<hr/></td><td align="left" valign="bottom">67.2<hr/></td></tr><tr><td align="left" valign="bottom">Urinary C-peptide excretion (&#x003bc;g/day)<hr/></td><td align="left" valign="bottom">43.5 (24.8-69.6)<hr/></td><td align="left" valign="bottom">67.4<hr/></td><td align="left" valign="bottom">14.4<hr/></td></tr><tr><td align="left" valign="bottom">C-peptide<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">(Glucagon stimulated test)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"> at 0&#x000a0;minutes (ng/mL)<hr/></td><td align="left" valign="bottom">0.9 (0.75-1.45)<hr/></td><td align="left" valign="bottom">1.9<hr/></td><td align="left" valign="bottom">0.4<hr/></td></tr><tr><td align="left" valign="bottom"> at 6&#x000a0;minutes (ng/mL)<hr/></td><td align="left" valign="bottom">2.3 (1.45-2.9)<hr/></td><td align="left" valign="bottom">3.0<hr/></td><td align="left" valign="bottom">0.8<hr/></td></tr><tr><td align="left" valign="bottom"> &#x00394; (ng/mL)<hr/></td><td align="left" valign="bottom">1.1 (0.65-1.40)<hr/></td><td align="left" valign="bottom">1.1<hr/></td><td align="left" valign="bottom">0.4<hr/></td></tr><tr><td align="left" valign="bottom">Insulin glargine (units/day)<hr/></td><td align="left" valign="bottom">14 (8.5-18.5)<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">13<hr/></td></tr><tr><td align="left" valign="bottom">Insulin glargine (units/kg)<hr/></td><td align="left" valign="bottom">0.2 (0.17-0.26)<hr/></td><td align="left" valign="bottom">0.15<hr/></td><td align="left" valign="bottom">0.23<hr/></td></tr><tr><td rowspan="2" align="left" valign="top">MAGE at the final CGM evaluation<hr/></td><td align="left" valign="bottom">60.5 (46.9-69.2)<hr/></td><td align="left" valign="bottom">61.3<hr/></td><td align="left" valign="bottom">87.6<hr/></td></tr><tr><td align="left" valign="bottom">(N&#x02009;=&#x02009;12)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">M-value at the final SMBG evaluation</td><td align="left">8.4 (4.3-14.1)</td><td align="left">24.2</td><td align="left">18.0</td></tr></tbody></table><table-wrap-foot><p>Median (interquartile range).</p></table-wrap-foot></table-wrap><p>No severe hypoglycemic events occurred. Regarding the CGM data, hypoglycemia of less than 70&#x000a0;mg/dL was rarely recorded from midnight until daytime (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Postprandial hyperglycemia can have a harmful effect on the cardiovascular outcome. In this study, ten patients were treated with as high a dose of metformin as they could tolerate; metformin is recommended as a drug of first choice [<xref ref-type="bibr" rid="B16">16</xref>] in combination with insulin glargine at STEP 0. The remaining six patients were treated with insulin glargine alone at STEP 0 because of an advanced age or a reduced renal function. The administration of basal insulin with or without metformin decreases the fasting glucose level and the overall glycemic profile, but in our cases, it was insufficient to postprandial hyperglycemia in 15 of the 16 cases. Many studies have discussed the combination of basal insulin with metformin or sufonylurea or both drugs [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. However, their mechanisms of action can make them insufficient to prevent postprandial hyperglycemia. Consequently, we prescribed miglitol and mitiglinide as a two-step treatment. Using our treatment regimen, 14 of the 16 patients achieved the target PBG as defined by the American Diabetes Association&#x02019;s recommendations [<xref ref-type="bibr" rid="B16">16</xref>]. Though the duration of the hospital stay might have contributed to the gradual improvement in the glucose level and might have influenced the achievement of the target PBG, the fact that most of the subjects eventually attained an ideal glycemic control using this regimen is noteworthy. In addition, CGM highlighted the precise profiles of glucose excursion, showing the effectiveness of the miglitol and mitiglinide in lowering daytime blood glucose levels without causing hypoglycemia during the night as well as showing the improvement in glucose fluctuations as a result of treatment with the two drugs in more detail.</p><p>The two patients who were unable to attain the target PBG suggest that the present regimen has some limitations. One patient was an obese, elderly man who was unable to take metformin because of his age. In this patient, insulin resistance might have limited the effect of mitiglinide. The other patient was a woman with the lowest serum C-peptide at 6&#x000a0;minutes in the glucagon test. For this patient, the effect of mitiglinide might have been limited by the impaired secretion of insulin.</p><p>In this study, we used two postprandial hypoglycemic agents. Alpha-glucosidase inhibitors, which delay the absorption of carbohydrates in food, decrease the postprandial glucose level without inducing the secretion of insulin [<xref ref-type="bibr" rid="B23">23</xref>]. As a result of this unique mechanism, alpha-glucosidase is effective for patients even if they have a comparatively long duration of diabetes and a severe deterioration of insulin secretion. In addition, miglitol provides incretin effects induced by GLP-1 secretion from L-cells [<xref ref-type="bibr" rid="B24">24</xref>]. Glinide is a short-acting insulin secretagogue that functions through the K<sub>ATP</sub> channel inhibition of &#x003b2; cells [<xref ref-type="bibr" rid="B25">25</xref>]. Mitiglinide also suppresses postprandial free fat acid levels [<xref ref-type="bibr" rid="B26">26</xref>]. These drugs decrease postprandial hyperglycemia effectively while causing fewer episodes of hypoglycemia and are relatively safe for patients with renal dysfunction and for elderly patients, in addition to being safe for long-term use.</p><p>Numerous studies have supported the effectiveness of basal insulin with sulfonylurea or metformin [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>] but as far as we know, few studies have examined the use of insulin glargine with postprandial hypoglycemic agents. Kim et al. reported the efficacy of adding either nateglinide or acarbose to insulin glargine, resulting in a 7-point reduction in the SMBG and with no difference in glucose variability between nateglinide and acarbose [<xref ref-type="bibr" rid="B27">27</xref>]. Hirose et al. investigated the effect of mitiglinide with insulin glargine after switching from multiple daily injections and reported that 15 out of 30 patients maintained a fair glucose control after switching to mitiglinide [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. These reports suggested the effectiveness of using postprandial hypoglycemic agents with long-acting basal insulin and also indicated the limitations of the addition of single postprandial hypoglycemic agents.</p><p>To improve postprandial hypoglycemia, dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 analogs are other choices for use in combination with basal insulin [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. We are also attempting to construct new regimens composed of basal insulin and multiple hypoglycemic agents, including DPP-4 inhibitors or GLP-1 analogs [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>Initiating basal insulin therapy in patients with poor glycemic control after the use of metformin is supported by the American Diabetes Association [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>] and the European Association for the Study of Diabetes [<xref ref-type="bibr" rid="B34">34</xref>]. In addition, this treatment regimen may lead to better glycemic control, compared with only basal insulin with metformin, because both the fasting and postprandial blood glucose levels can be controlled. This regimen might also serve as a go-between for frequent insulin injections therapy.</p><p>This study had several limitations including the relatively small number of subjects, the absence of a control group, and the short-term results for inpatients. The patients&#x02019; satisfaction level after receiving this regimen and long-term diabetic complications, cardiovascular disease, and mortality also need to be evaluated. In addition, larger studies are needed to evaluate the reduction of hypoglycemia associated with this regimen. Confirming this hypothesis, further studies are required to confirm the efficacy of this regimen in outpatients; furthermore, the regimen should be simplified before being administered to outpatients.</p><p>Once such points have been clarified, our structured treatment regimen might be beneficial for many type 2 diabetes patients requiring insulin therapy.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In conclusion, in a pilot study of a two-step regimen consisting of the addition of postprandial hypoglycemic agents, more than 80% of the patients achieved a good glucose profile, indicating the potent efficacy of the two-step administration of postprandial hypoglycemic agents with basal insulin therapy.</p></sec><sec><title>Abbreviations</title><p>OHAs: Oral hypoglycemic agents; CGM: Continuous glucose monitoring; SMBG: Self-monitoring blood glucose; FBG: Fasting blood glucose; PBG: Postprandial 2-hour blood glucose; SDs: Standard deviations; AUC: Area under the curves; DPP-4 inhibitor: Dipeptidyl peptidase-4 inhibitor; eGFR: Estimated glomerular filtration rate.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>NI conceptualized the idea for the study, collected the data, performed the statistical analysis, and wrote the paper. TT participated in the design of the study, joined the discussion, and was involved in drafting the manuscript. R Y-H participated in the design of the study, joined the discussion, and was involved in drafting the manuscript. MKishimoto jointed the discussion and was involved in drafting the manuscript. HK and HN joined the discussion. MKakei joined the discussion and supervised the work. MN participated in the design of the study, supervised the work, and joined the discussion. All authors have read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1: Table S1</title><p>Characteristics of the patients who reached the target PBG at STEP 1 and the patients who proceeded to STEP2.</p></caption><media xlink:href="1758-5996-6-48-S1.doc"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2: Table S2</title><p>Detailed results of area under the curve for Continuous Glucose Monitoring and glucose fluctuation STEP 1 and STEP 2.</p></caption><media xlink:href="1758-5996-6-48-S2.doc"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgments</title><p>This work was funded by a Health Sciences Research Grant (Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus H25-016) from the Ministry of Health, Labour and Welfare of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><collab>The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus</collab><article-title>Report of the Committee on the classification and diagnostic criteria of diabetes mellitus</article-title><source>Diabetol Int</source><year>2010</year><volume>1</volume><fpage>2</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s13340-010-0006-7</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Kuzuya</surname><given-names>T</given-names></name><name><surname>Hagura</surname><given-names>R</given-names></name><name><surname>Yoshinaga</surname><given-names>H</given-names></name><article-title>Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus</article-title><source>Diabet Med</source><year>1996</year><volume>13</volume><fpage>S109</fpage><lpage>S119</lpage><pub-id pub-id-type="pmid">8894494</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Yamamoto-Honda</surname><given-names>R</given-names></name><name><surname>Osame</surname><given-names>K</given-names></name><name><surname>Kitazato</surname><given-names>H</given-names></name><name><surname>Shinkai-Goromaru</surname><given-names>M</given-names></name><name><surname>Isogawa</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Kawzu</surname><given-names>S</given-names></name><name><surname>Akanuma</surname><given-names>Y</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><article-title>Insulin secretion and insulin sensitivity in Japanese patients with Type 2 diabetes: a cross-sectional study comparing the homeostasis model assessment-2 (HOMA2) indexes and indexes derived from the oral glucose tolerance test</article-title><source>Diabetology Int</source><year>2011</year><volume>2</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1007/s13340-011-0024-0</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Thorne</surname><given-names>KI</given-names></name><name><surname>Farmer</surname><given-names>AJ</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Keenan</surname><given-names>JF</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Levy</surname><given-names>JC</given-names></name><collab>4-T Study Group</collab><article-title>Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>1716</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa075392</pub-id><pub-id pub-id-type="pmid">17890232</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Bretzel</surname><given-names>RG</given-names></name><name><surname>Nuber</surname><given-names>U</given-names></name><name><surname>Landgraf</surname><given-names>W</given-names></name><name><surname>Owens</surname><given-names>DR</given-names></name><name><surname>Brandley</surname><given-names>C</given-names></name><name><surname>Linn</surname><given-names>T</given-names></name><name><surname>Bretzel</surname><given-names>A</given-names></name><name><surname>Nuber</surname><given-names>U</given-names></name><name><surname>Landgraf</surname><given-names>W</given-names></name><name><surname>Owens</surname><given-names>DR</given-names></name><name><surname>Brandley</surname><given-names>C</given-names></name><name><surname>Linn</surname><given-names>T</given-names></name><article-title>Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>1073</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60485-7</pub-id><pub-id pub-id-type="pmid">18374840</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Monnier</surname><given-names>L</given-names></name><name><surname>Colette</surname><given-names>C</given-names></name><name><surname>Rabasa-Lhoret</surname><given-names>R</given-names></name><name><surname>Lapinski</surname><given-names>H</given-names></name><name><surname>Caubel</surname><given-names>C</given-names></name><name><surname>Avignon</surname><given-names>A</given-names></name><name><surname>Boniface</surname><given-names>H</given-names></name><article-title>Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><issue>4</issue><fpage>737</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.4.737</pub-id><pub-id pub-id-type="pmid">11919134</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Yamamoto-Honda</surname><given-names>R</given-names></name><name><surname>Kitazato</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>C</given-names></name><name><surname>Akanuma</surname><given-names>Y</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><article-title>Distribution of blood glucose and correlation between blood glucose and hemoglobin A1c levels in diabetic outpatients</article-title><source>Endocr J</source><year>2008</year><volume>55</volume><issue>5</issue><fpage>913</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K08E-071</pub-id><pub-id pub-id-type="pmid">18612182</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><collab>DECODE Study Group, on behalf of the European Diabetes Epidemiology Group</collab><article-title>Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria</article-title><source>Arch Intern Med</source><year>2001</year><volume>161</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">11176766</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>M</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name><name><surname>Grobbee</surname><given-names>D</given-names></name><name><surname>Hamet</surname><given-names>P</given-names></name><name><surname>Harrap</surname><given-names>S</given-names></name><name><surname>Heller</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Poulter</surname><given-names>N</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Bompoint</surname><given-names>S</given-names></name><name><surname>de Galan</surname><given-names>BE</given-names></name><name><surname>Joshi</surname><given-names>R</given-names></name><name><surname>Travert</surname><given-names>F</given-names></name><collab>The ADVANCE Collaborative Group</collab><article-title>Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2560</fpage><lpage>2572</lpage><pub-id pub-id-type="pmid">18539916</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Ceriello</surname><given-names>A</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Leiter</surname><given-names>L</given-names></name><name><surname>Monnier</surname><given-names>L</given-names></name><name><surname>Moses</surname><given-names>A</given-names></name><name><surname>Owens</surname><given-names>D</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><collab>for the International Prandial Glucose Regulation (PGR) Study Group</collab><article-title>Postprandial glucose regulation and diabetic complications</article-title><source>Arch Intern Med</source><year>2004</year><volume>164</volume><fpage>2090</fpage><lpage>2095</lpage><pub-id pub-id-type="doi">10.1001/archinte.164.19.2090</pub-id><pub-id pub-id-type="pmid">15505121</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Cavalot</surname><given-names>F</given-names></name><name><surname>Pagliarino</surname><given-names>A</given-names></name><name><surname>Valle</surname><given-names>M</given-names></name><name><surname>Di Martino</surname><given-names>L</given-names></name><name><surname>Bonomo</surname><given-names>K</given-names></name><name><surname>Massucco</surname><given-names>P</given-names></name><name><surname>Anfossi</surname><given-names>G</given-names></name><name><surname>Trovati</surname><given-names>M</given-names></name><article-title>Postprandial blood glucose predicts cardiovascular events and all-cause mortality in Type2 Diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga diabetes study</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><fpage>2237</fpage><lpage>2243</lpage><pub-id pub-id-type="doi">10.2337/dc10-2414</pub-id><pub-id pub-id-type="pmid">21949221</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Shiraiwa</surname><given-names>T</given-names></name><name><surname>Kaneto</surname><given-names>H</given-names></name><name><surname>Miyatsuka</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Kawashima</surname><given-names>A</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Imano</surname><given-names>E</given-names></name><name><surname>Matsuhisa</surname><given-names>M</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Yamasaki</surname><given-names>Y</given-names></name><article-title>Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>2806</fpage><lpage>2807</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.11.2806</pub-id><pub-id pub-id-type="pmid">16249562</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Chittari</surname><given-names>MV</given-names></name><name><surname>MacTernan</surname><given-names>P</given-names></name><name><surname>Bawazeer</surname><given-names>N</given-names></name><name><surname>Constantinides</surname><given-names>K</given-names></name><name><surname>Ciotola</surname><given-names>M</given-names></name><name><surname>O&#x02019;Hare</surname><given-names>JP</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Ceriello</surname><given-names>A</given-names></name><article-title>Impact of acute hyperglycaemia on endothelial function and retinal vascular reactivity in patients with Type 2 diabetes</article-title><source>Diabet Med</source><year>2011</year><volume>28</volume><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2010.03223.x</pub-id><pub-id pub-id-type="pmid">21204962</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Goto</surname><given-names>A</given-names></name><name><surname>Arah</surname><given-names>OA</given-names></name><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><article-title>Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis</article-title><source>BMJ</source><year>2013</year><volume>347</volume><fpage>f4533</fpage><pub-id pub-id-type="doi">10.1136/bmj.f4533</pub-id><pub-id pub-id-type="pmid">23900314</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Tsujimoto</surname><given-names>T</given-names></name><name><surname>Yamamoto-Honda</surname><given-names>R</given-names></name><name><surname>Kajio</surname><given-names>H</given-names></name><name><surname>Kishimoto</surname><given-names>M</given-names></name><name><surname>Noto</surname><given-names>H</given-names></name><name><surname>Hachiya</surname><given-names>R</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Kakei</surname><given-names>M</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><article-title>Vital Signs, QT Prolongation, and Newly Diagnosed Cardiovascular Disease during Severe Hypoglycemia in Type 1 and Type 2 Diabetic Patients</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><issue>1</issue><fpage>217</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2337/dc13-0701</pub-id><pub-id pub-id-type="pmid">23939540</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><collab>American Diabetes Association</collab><article-title>Standards of Medical Care in Diabetes-2013</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><issue>Supplement</issue><fpage>S11</fpage><lpage>S66</lpage><pub-id pub-id-type="pmid">23264422</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Schichtkrull</surname><given-names>J</given-names></name><name><surname>Munck</surname><given-names>O</given-names></name><name><surname>Jersild</surname><given-names>M</given-names></name><article-title>The M-Value, an index of Blood-Sugar Control in Diabetics</article-title><source>Acta Med Scand</source><year>1965</year><volume>177</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">14251860</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>W&#x000f3;jcicki</surname><given-names>JM</given-names></name><article-title>Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull &#x0201c;M&#x0201d;-value</article-title><source>Horm Metab Res</source><year>1995</year><volume>27</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1055/s-2007-979895</pub-id><pub-id pub-id-type="pmid">7729784</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Service</surname><given-names>FJ</given-names></name><name><surname>Molnar</surname><given-names>GD</given-names></name><name><surname>Rosevear</surname><given-names>JW</given-names></name><name><surname>Ackerman</surname><given-names>E</given-names></name><name><surname>Gatewood</surname><given-names>LC</given-names></name><name><surname>William</surname><given-names>FT</given-names></name><article-title>Mean amplitude of glycemic excursions, a measure of diabetic instability</article-title><source>Diabetes</source><year>1970</year><volume>19</volume><issue>9</issue><fpage>644</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">5469118</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Yuki-J&#x000e4;rvinen</surname><given-names>H</given-names></name><name><surname>Kauppinen-M&#x000e4;kelin</surname><given-names>R</given-names></name><name><surname>Tiikkainen</surname><given-names>M</given-names></name><name><surname>V&#x000e4;h&#x000e4;talo</surname><given-names>M</given-names></name><name><surname>Virtamo</surname><given-names>H</given-names></name><name><surname>Nikkil&#x000e4;</surname><given-names>K</given-names></name><name><surname>Tulokas</surname><given-names>T</given-names></name><name><surname>Hulme</surname><given-names>S</given-names></name><name><surname>Hardy</surname><given-names>K</given-names></name><name><surname>McNulty</surname><given-names>S</given-names></name><name><surname>H&#x000e4;nninen</surname><given-names>J</given-names></name><name><surname>Lev&#x000e4;nen</surname><given-names>H</given-names></name><name><surname>Lahdenper&#x000e4;</surname><given-names>S</given-names></name><name><surname>Lehtonen</surname><given-names>R</given-names></name><name><surname>Ryysy</surname><given-names>L</given-names></name><article-title>Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>442</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1007/s00125-005-0132-0</pub-id><pub-id pub-id-type="pmid">16456680</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Home</surname><given-names>PD</given-names></name><name><surname>Larsen</surname><given-names>J</given-names></name><name><surname>Koenen</surname><given-names>C</given-names></name><name><surname>Schernthaner</surname><given-names>G</given-names></name><article-title>A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administrated as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>408</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1007/s00125-007-0911-x</pub-id><pub-id pub-id-type="pmid">18204830</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Gill</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Leahy</surname><given-names>J</given-names></name><article-title>An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycemic control and hypoglycemia</article-title><source>Diabetes, Obesity and Metabolism</source><year>2011</year><volume>13</volume><fpage>814</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01412.x</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Kishimoto</surname><given-names>M</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><article-title>A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers</article-title><source>Cardiovasc Diabetol</source><year>2011</year><volume>10</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-10-115</pub-id><pub-id pub-id-type="pmid">22189184</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Patric</surname><given-names>P</given-names></name><name><surname>Wishart</surname><given-names>J</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name><article-title>The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics</article-title><source>Diabetes Obes Metab</source><year>2002</year><volume>4</volume><issue>5</issue><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1046/j.1463-1326.2002.00219.x</pub-id><pub-id pub-id-type="pmid">12190996</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Sunaga</surname><given-names>Y</given-names></name><name><surname>Gonoi</surname><given-names>T</given-names></name><name><surname>Shibasaki</surname><given-names>T</given-names></name><name><surname>Ichikawa</surname><given-names>K</given-names></name><name><surname>Kusama</surname><given-names>H</given-names></name><name><surname>Yano</surname><given-names>H</given-names></name><name><surname>Seino</surname><given-names>S</given-names></name><article-title>The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K&#x02009;+&#x02009;channels and insulin secretion: comparison with the sulfonylureas and nateglinide</article-title><source>Eur J Pharmacol</source><year>2001</year><volume>431</volume><issue>1</issue><fpage>199</fpage><lpage>225</lpage></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Ojima</surname><given-names>K</given-names></name><name><surname>Fuujimori</surname><given-names>Y</given-names></name><name><surname>Aoyagi</surname><given-names>I</given-names></name><name><surname>Kusama</surname><given-names>H</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Shibata</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><article-title>Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats</article-title><source>Endocrine</source><year>2006</year><volume>29</volume><issue>2</issue><fpage>309</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1385/ENDO:29:2:309</pub-id><pub-id pub-id-type="pmid">16785606</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Suk</surname><given-names>JH</given-names></name><name><surname>Kwon</surname><given-names>MJ</given-names></name><name><surname>Chung</surname><given-names>HS</given-names></name><name><surname>Yoon</surname><given-names>CS</given-names></name><name><surname>Jun</surname><given-names>HJ</given-names></name><name><surname>Ko</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>TK</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Oh</surname><given-names>MK</given-names></name><name><surname>Rhee</surname><given-names>BD</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><article-title>Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes</article-title><source>Diabetes Res Clin Pract</source><year>2011</year><volume>92</volume><issue>3</issue><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2011.01.022</pub-id><pub-id pub-id-type="pmid">21376417</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Yoshihara</surname><given-names>T</given-names></name><name><surname>Kumashiro</surname><given-names>N</given-names></name><name><surname>Kanazawa</surname><given-names>Y</given-names></name><name><surname>Mita</surname><given-names>T</given-names></name><name><surname>Sakurai</surname><given-names>Y</given-names></name><name><surname>Kawai</surname><given-names>J</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Motojima</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Kanazawa</surname><given-names>A</given-names></name><name><surname>Miwa</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Kanno</surname><given-names>R</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Uchino</surname><given-names>H</given-names></name><name><surname>Watada</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Kawamori</surname><given-names>R</given-names></name><name><surname>Hirose</surname><given-names>T</given-names></name><article-title>Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus</article-title><source>Endocr J</source><year>2006</year><volume>53</volume><issue>1</issue><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1507/endocrj.53.67</pub-id><pub-id pub-id-type="pmid">16543674</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Kumashiro</surname><given-names>N</given-names></name><name><surname>Yoshihara</surname><given-names>T</given-names></name><name><surname>Kanazawa</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Watada</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Fujitani</surname><given-names>Y</given-names></name><name><surname>Kawamori</surname><given-names>R</given-names></name><name><surname>Hirose</surname><given-names>T</given-names></name><article-title>Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study</article-title><source>Endocr J</source><year>2007</year><volume>54</volume><issue>1</issue><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K06-153</pub-id><pub-id pub-id-type="pmid">17185877</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Takahara</surname><given-names>M</given-names></name><name><surname>Shiraiwa</surname><given-names>T</given-names></name><name><surname>Kaneto</surname><given-names>H</given-names></name><name><surname>Katakami</surname><given-names>N</given-names></name><name><surname>Matsuoka</surname><given-names>TA</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name><article-title>Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy</article-title><source>Endocr J</source><year>2013</year><volume>59</volume><issue>12</issue><fpage>1131</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">22850206</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Arnolds</surname><given-names>S</given-names></name><name><surname>Dellweg</surname><given-names>S</given-names></name><name><surname>Clair</surname><given-names>J</given-names></name><name><surname>Dain</surname><given-names>MP</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Rave</surname><given-names>K</given-names></name><name><surname>Kapitza</surname><given-names>C</given-names></name><article-title>Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>1509</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.2337/dc09-2191</pub-id><pub-id pub-id-type="pmid">20357372</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Kishimoto</surname><given-names>M</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><article-title>Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes</article-title><source>Diabetes Ther</source><year>2012</year><volume>3</volume><fpage>11</fpage><pub-id pub-id-type="pmid">23055336</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><collab>American Diabetes Association</collab><article-title>Standards of Medical Care in Diabetes-2014</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><fpage>S14</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">24357209</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>AL</given-names></name><name><surname>Tsapas</surname><given-names>A</given-names></name><name><surname>Wender</surname><given-names>R</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><collab>American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD)</collab><article-title>Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><issue>6</issue><fpage>1364</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.2337/dc12-0413</pub-id><pub-id pub-id-type="pmid">22517736</pub-id></mixed-citation></ref></ref-list></back></article>